Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis

Bohuslav Melichar, Helena Hornychová, Hana Kalábová, Hana Bašová, Jindřiška Mergancová, Hana Urminská, Pavel Jandík, Vladimír Červinka, Jan Laco, Aleš Ryška

. 2012 ; 29 (4) : 2577-2585.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc13031934

Grantová podpora
NS10286 MZ0 CEP - Centrální evidence projektů

Neoadjuvant chemotherapy is being increasingly used in the treatment of breast carcinoma. We performed a single-center retrospective analysis of the results of neoadjuvant therapy in 376 breast carcinoma patients treated with three different regimens combining doxorubicin and paclitaxel (AT), dose-dense doxorubicin and cyclophosphamide with sequential weekly paclitaxel (DD AC-P), or the combination of trastuzumab with chemotherapy (DD AC-PT). The expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor (HER)-2 was determined immunohistochemically. Pathological response was determined in 318 patients. Pathological complete response (pCR) was observed in 18% of patients. The pCR rate was significantly higher in patients treated with DD regimen (22 vs. 13%) and younger than 55 years (23 vs. 13%). The pCR rate was higher in patients with triple negative (TN) tumors (43%) and tumors over-expressing HER-2 (HER-2+; 28%) compared to patients with ER- or PR-positive tumors not expressing HER-2 (ER/PR+HER-2-; 6%). In patients with TN tumors pCR rate was significantly higher after treatment with DD AC-P compared to AT (61 vs. 22%, p=0.005). pCR was associated with significantly improved relapse-free survival (RFS) and overall survival (OS), but when analysis was performed based on tumor phenotype, the difference was significant only in patients with TN tumors. In multivariate analysis, pCR, stage, and ER expression were significant predictors of RFS, while pCR, stage, ER and DD regimen were significant predictors of OS. In conclusion, present data indicate superiority of a DD regimen in obtaining pCR in patients with breast carcinoma treated with neoadjuvant chemotherapy. The difference in efficacy is due mostly to markedly higher pCR rate in patients with TN tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc13031934
003      
CZ-PrNML
005      
20141114124235.0
007      
ta
008      
131002s2012 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12032-012-0195-y $2 doi
035    __
$a (PubMed)22392196
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Melichar, Bohuslav $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic; Department of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic. bohuslav.melichar@fnol.cz
245    10
$a Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma: a retrospective analysis / $c Bohuslav Melichar, Helena Hornychová, Hana Kalábová, Hana Bašová, Jindřiška Mergancová, Hana Urminská, Pavel Jandík, Vladimír Červinka, Jan Laco, Aleš Ryška
520    9_
$a Neoadjuvant chemotherapy is being increasingly used in the treatment of breast carcinoma. We performed a single-center retrospective analysis of the results of neoadjuvant therapy in 376 breast carcinoma patients treated with three different regimens combining doxorubicin and paclitaxel (AT), dose-dense doxorubicin and cyclophosphamide with sequential weekly paclitaxel (DD AC-P), or the combination of trastuzumab with chemotherapy (DD AC-PT). The expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor (HER)-2 was determined immunohistochemically. Pathological response was determined in 318 patients. Pathological complete response (pCR) was observed in 18% of patients. The pCR rate was significantly higher in patients treated with DD regimen (22 vs. 13%) and younger than 55 years (23 vs. 13%). The pCR rate was higher in patients with triple negative (TN) tumors (43%) and tumors over-expressing HER-2 (HER-2+; 28%) compared to patients with ER- or PR-positive tumors not expressing HER-2 (ER/PR+HER-2-; 6%). In patients with TN tumors pCR rate was significantly higher after treatment with DD AC-P compared to AT (61 vs. 22%, p=0.005). pCR was associated with significantly improved relapse-free survival (RFS) and overall survival (OS), but when analysis was performed based on tumor phenotype, the difference was significant only in patients with TN tumors. In multivariate analysis, pCR, stage, and ER expression were significant predictors of RFS, while pCR, stage, ER and DD regimen were significant predictors of OS. In conclusion, present data indicate superiority of a DD regimen in obtaining pCR in patients with breast carcinoma treated with neoadjuvant chemotherapy. The difference in efficacy is due mostly to markedly higher pCR rate in patients with TN tumors.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a nádory prsu $x chemie $x farmakoterapie $x mortalita $x patologie $7 D001943
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a receptor erbB-2 $x analýza $7 D018719
650    _2
$a receptory pro estrogeny $x analýza $7 D011960
650    _2
$a receptory progesteronu $x analýza $7 D011980
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hornychová, Helena $u Department of Pathology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
700    1_
$a Kalábová, Hana $u Department of Oncology, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
700    1_
$a Bašová, Hana $u Department of Oncology and Radiotherapy, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
700    1_
$a Mergancová, Jindřiška $u Department of Surgery, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
700    1_
$a Urminská, Hana $u Department of Radiology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
700    1_
$a Jandík, Pavel $u Department of Surgery, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
700    1_
$a Cervinka, Vladimír $u Department of Pathology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
700    1_
$a Laco, Jan $u Department of Pathology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
700    1_
$a Ryška, Aleš $u Department of Pathology, Charles University Medical School and Teaching Hospital, Hradec Kralove, Czech Republic
773    0_
$w MED00012126 $t Medical oncology (Northwood, London, England) $x 1559-131X $g Roč. 29, č. 4 (2012), s. 2577-2585
856    41
$u https://pubmed.ncbi.nlm.nih.gov/22392196 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20131002 $b ABA008
991    __
$a 20141114124250 $b ABA008
999    __
$a ok $b bmc $g 996021 $s 830379
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 29 $c 4 $d 2577-2585 $i 1559-131X $m Medical oncology $n Med Oncol $x MED00012126
GRA    __
$a NS10286 $p MZ0
LZP    __
$a Pubmed-20131002

Najít záznam

Citační ukazatele

Možnosti archivace